Activity of antioxidative enzymes and concentration of malondialdehyde as oxidative status markers in women with newly diagnosed Graves-Basedow disease and after thiamazole therapy leading to euthyroidism.
INTRODUCTION. Hyperthyroidism in the course of Graves-Basedow disease leads to intensification of oxidative processes and increased production of free oxygen radicals. It results in abnormal oxidative status of the organism.


OBJECTIVE
Aim of this work was to assess the dynamics of oxidative status changes in women with Graves-Basedow disease before and after treatment with thiamazole.


METHODS
Studies were carried out in 20 women with newly diagnosed hyperthyroidism in the course of Graves-Basedow disease and in 15 healthy women. Measurements of activity of antioxidant enzymes--superoxide dismutase (cytosolic copper/zinc isoform--Cu/ZnSOD, mitochondrial manganese isoform--MnSOD and extracellular copper/zinc isoform--EC-SOD) and glutathione peroxidase (GPx), as well as of malondialdehyde (MDA) concentration were performed twice, i.e. before the treatment and after 3-7 months of thiamazole therapy (euthyroidism).


RESULTS
Before the treatment, higher MnSOD plasma activity and lower EC-SOD activity were observed in women with hyperthyroidism in comparison with the control group, whereas the erythrocyte Cu/ZnSOD activity did not differ between the groups. Besides, women with hyperthyroidism had higher GPx activity in red blood cells. In this group studies have demonstrated higher plasma MDA levels, without any differences between the groups in MDA levels in red blood cells. After thiamazole therapy no differences could be demonstrated in MnSOD, EC-SOD, Cu/ZnSOD and GPx activities and MDA level between the groups.


CONCLUSIONS
Women with hyperthyroidism in the course of Graves-Basedow disease experience abnormal oxidative status of the organism, and induction of euthyroidism after therapy with thiamazole results in resolution of these abnormalities.
Rybus-Kalinowska
Barbara
B
Chair and Institute of Physiology, Zabrze, Poland. markal13@oxygen.pl
Zwirska-Korczala
Krystyna
K
Kalinowski
Mariusz
M
Kukla
Michał
M
Birkner
Ewa
E
Jochem
Jerzy
J
D000328:Adult; D000975:Antioxidants / Q000378:metabolism*; D013956:Antithyroid Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood; D006111:Graves Disease / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D008315:Malondialdehyde / Q000097:blood*; D008713:Methimazole / Q000008:administration & dosage*; D008875:Middle Aged; D018384:Oxidative Stress; D013482:Superoxide Dismutase / Q000097:blood; D016896:Treatment Outcome
D000975:Antioxidants; D013956:Antithyroid Agents; D015415:Biomarkers; D008315:Malondialdehyde; D008713:Methimazole; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase